Navigation Links
P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth
Date:10/29/2008

net earnings. The company's long-term target is to generate free cash at or above 90 percent of net earnings. Free cash flow productivity is also one of the measures used to evaluate senior management. The reconciliation of free cash flow and free cash flow productivity is provided below ($ millions):

Free Free

Operating Capital Cash Net Cash Flow

Cash Flow Spending Flow Earnings Productivity

Jul - Sep $3,251 $(699) $2,552 $3,348 76 %

The Procter & Gamble Company

Exhibit 2: Folgers Coffee Supplement

As previously disclosed, the company plans to separate the Folgers business in the October - December quarter. This business is comprised of P&G's coffee category, a component of P&G's Snacks, Coffee and Pet Health reportable segment, as well as the coffee portion of the P&G Professional (PGP) business.

The company provided a brief summary of results for the Folgers business for the July - September quarter. These results represent the business as currently operated as a component of P&G, including PGP, and are not directly comparable to the historical results of Folgers as a stand-alone entity as presented in its recently filed registration statement related to the transaction with The J. M. Smucker Company. The differences are primarily related to P&G management reporting conventions and do not have a material impact on the underlying business trends.

Folgers net sales for July - September quarter were up 11 percent to $445 million primarily due to the benefit of pricing actions in prior periods to recover higher green coffee bean costs. Volume increased one percent as gains in retail channels were offset by a decline in PGP volume. Market share was flat period over period.

After tax earnings for the Folgers business for the July - September qua
'/>"/>

SOURCE The Procter & Gamble Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Cardinal Health Reports First Quarter Results
2. uKarma Reports Progress With International Distribution Agreement for Its Xflowsion DVD Series
3. STAAR Surgical Reports 33% Third Quarter Revenue Growth
4. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
5. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
6. LCA-Vision Reports Third Quarter 2008 Financial Results
7. Universal Health Services, Inc. Reports 2008 Third Quarter Results
8. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
9. Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009
10. WellPoint Reports Third Quarter 2008 Results
11. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...CAGO, Jan. 8 Allscripts-...ipts Healthcare Solutions, Inc. (Allscripts or,th...for the three and six,months ended November 30, 2...in/prnh/20061005/ALLSCRIPTSLOGO-b ) , The C...d November 30, 2008,include results from legacy A...
(Date:1/8/2009)...TON, Jan. 8 The Pew Cha...has been named director, chemical and food safety ...y program. Olson, who was formerly deputy staff di... on Environment and Public Works, brings nearly 25...onsumer advocacy to Pew. , , "We are excited t...
(Date:1/8/2009)...une Promoted to Principal. Christine Siu and Jaso...INNEAPOLIS, SAN FRANCISCO and STAMFORD, Conn., Jan...s, a health care venture capital firm that invests... today announced the promotion of three members of...d to Principal. Christine Siu and Jason Brown hav...
(Date:1/8/2009)...POLIS, Jan. 8 A proposa...diers and Sailors Children,s Home has prompted the...ana to revamp its annual Mid-Winter conference Jan...ate its members, nearly unanimous opposition to th...ides more than $50,000 in direct and in-kind suppo...
Breaking Medicine News(10 mins):Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 13Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2Health News:Thomas, McNerney & Partners Promotes Three Members of Its Investment Team 2
...ers in a recent study on both mice and humans are ...to their body than others. Did you know that if yo..., say, //or a doughnut - the amount of cholesterol... Experts know that high cholesterol is linked to h...
...study are trying to observe why surgery may trigg...re ongoing. It's long been known that some older p...l functions after an operation// - a condition kno....Often relatives will say that the person has 'nev...
...ers it is observed that a drug already being used ...fective male contraceptive. Researchers hypothesiz...een approved in Europe to treat Gaucher's disease,...affects the metabolism of sugar-fat compounds esse...
...y, a protein in the eye has prevented and stopped ...earchers say this could lead to promising treatmen...e sclerosis and type 1 diabetes. Scientists from t...Boston found the factor alpha-MSH can be harnessed...
Other Medicine News:
(Date:1/6/2009)...ts from prior U.S., U.K. and China Trials , , S...Inc. (VTI), a development stage company targeting ...has begun for a randomized, controlled, multi-cent...racorporeal Liver Assist Device (ELAD) as a treatm...der three protocols. The study is open for enrollm...
(Date:1/6/2009)...e/ -- Cequent Pharmaceuticals, a pioneer in the de...treatments to prevent and treat human disease, ann...uccessful toxicology study of its candidate CEQ501...eting the primary oncogene (beta-catenin, CTNNB1) ... inherited gastrointestinal disease that causes hu...
(Date:1/5/2009)...swire/ -- Women undergoing in vitro,fertilization...port early,pregnancy, but the intramuscular injec...inful for patients. Formulations of progesterone ...ous injection or vaginal suppository may offer,si... With patient well-being a constant focus, Fert...
(Date:12/27/2008)...ewswire/ -- According to the latest,science, resv...est doses of,resveratrol plus an array of antioxi...asses of aged, red wine, rather than resveratrol a...i-bin/prnh/20080603/LATU039 ) , The most r...s to prolong,the life of laboratory mice. In fac...
Breaking Medicine Technology:ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 3IMTEC Introduces the SPRITE CT System 21584 1IMTEC Introduces the SPRITE CT System 21584 2HMS Holdings Corp to Present at Jefferies 2nd Annual Healthcare Conference 21582 1COSE Introduces Health Incentives Wellness Programs for Medium Size Businesses 21580 1COSE Introduces Health Incentives Wellness Programs for Medium Size Businesses 21580 2Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates 5939 1Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates 5939 2Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates 5939 3Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates 5939 4Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates 5939 5
...gression-free survival in,the SPARC Phase 3 trial ...isk of disease progression for patients receiving,...e use,geographies, as well as presence or absence...tCall/ -- Pharmion,Corporation and GPC Biotech AG ...a from the double-blind, randomized satraplatin Ph...
...ts EORTC 40983 (EPOC),Intergroup Study Results, CH...ults of the,randomized phase III EORTC 40983 Inter...rst time that peri-operative (pre and post,surgery...combination with a standard chemotherapy regimen f...V)) given to patients with,resectable liver metast...
Other Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 2The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 3The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 4The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 5The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 6The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 7The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 8The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 9
The herbal extracts, vitamins, minerals, and antioxidants in this formula increases circulation to ocular tissue, improves tear quality, and maintains healthy function of the lens and retina of the e
...-Rads QCNet is the industry-leading portal to QC i... easy and rapid way to access their quality contro...ternet. UnityWeb enables Bio-Rad customers to acce...boratory Reports, as well as convenient online dat...
The ACCU-CHEK Spirit insulin pump system offers frequent and precise delivery of the basal rate and rapid infusion of the bolus. The ACCU-CHEK Spirit pump is safe, reliable and easy to program.
The MiniMed Paradigm REAL-Time System is the world's first system to integrate an insulin pump with REAL-Time continuous glucose monitoring, taking diabetes management to a level you just can't achie
Medicine Products: